GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RBC Bioscience Corp (ROCO:6848) » Definitions » EV-to-EBITDA

RBC Bioscience (ROCO:6848) EV-to-EBITDA : 16.95 (As of May. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is RBC Bioscience EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, RBC Bioscience's enterprise value is NT$628.5 Mil. RBC Bioscience's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was NT$37.1 Mil. Therefore, RBC Bioscience's EV-to-EBITDA for today is 16.95.

The historical rank and industry rank for RBC Bioscience's EV-to-EBITDA or its related term are showing as below:

ROCO:6848' s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.11   Med: 16.79   Max: 21.29
Current: 16.96

During the past 7 years, the highest EV-to-EBITDA of RBC Bioscience was 21.29. The lowest was 2.11. And the median was 16.79.

ROCO:6848's EV-to-EBITDA is ranked worse than
63.19% of 451 companies
in the Biotechnology industry
Industry Median: 9.67 vs ROCO:6848: 16.96

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), RBC Bioscience's stock price is NT$15.95. RBC Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$0.490. Therefore, RBC Bioscience's PE Ratio for today is 32.55.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


RBC Bioscience EV-to-EBITDA Historical Data

The historical data trend for RBC Bioscience's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RBC Bioscience EV-to-EBITDA Chart

RBC Bioscience Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - - 14.07 19.66 17.00

RBC Bioscience Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.07 - 19.66 - 17.00

Competitive Comparison of RBC Bioscience's EV-to-EBITDA

For the Biotechnology subindustry, RBC Bioscience's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RBC Bioscience's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RBC Bioscience's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where RBC Bioscience's EV-to-EBITDA falls into.



RBC Bioscience EV-to-EBITDA Calculation

RBC Bioscience's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=628.455/37.072
=16.95

RBC Bioscience's current Enterprise Value is NT$628.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RBC Bioscience's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was NT$37.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RBC Bioscience  (ROCO:6848) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

RBC Bioscience's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=15.95/0.490
=32.55

RBC Bioscience's share price for today is NT$15.95.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RBC Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$0.490.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


RBC Bioscience EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of RBC Bioscience's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


RBC Bioscience (ROCO:6848) Business Description

Traded in Other Exchanges
N/A
Address
Lane 235, Baoqiao Road, 3rd Floor, No. 132, New Taipei City, TWN, 23145
RBC Bioscience Corp is a bio sciences company. Its products include Real Genomics, MagCore Automated Nucleic Acid Extractor, and MagCore Nucleic Acid Extraction KIT.

RBC Bioscience (ROCO:6848) Headlines

No Headlines